Latest News on OPCH

Financial News Based On Company


Advertisement
Advertisement

Option Care Health (OPCH) GC exercises 812 RSUs and reports updated share holdings

https://www.stocktitan.net/sec-filings/OPCH/form-4-option-care-health-inc-insider-trading-activity-eaceee855a71.html
Option Care Health's GC & Corporate Secretary, Collin Smyser, exercised 812 Restricted Stock Units on May 19, 2026, which converted into common shares. Concurrently, 360 common shares were disposed of to cover tax obligations. After these transactions, Smyser directly holds 75,372 shares and indirectly holds 2,500 shares through a revocable trust, reflecting routine equity compensation vesting rather than discretionary trading.

Securities Fraud Investigation Into Option Care Health, Inc. (OPCH) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

https://www.mycarrollcountynews.com/online_features/press_releases/article_989e81a0-8a5b-502d-a28e-a9771adc3211.html
Glancy Prongay Wolke & Rotter LLP is continuing its securities fraud investigation into Option Care Health, Inc. (OPCH) on behalf of investors who lost money. This follows Option Care Health's release of Q1 2026 financial results that missed consensus estimates and a lowering of its full-year 2026 revenue guidance, causing a significant drop in the stock price. The law firm is urging affected shareholders to contact them to explore potential claims.

Securities Fraud Investigation Into Option Care Health, Inc. (OPCH) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

https://www.businesswire.com/news/home/20260520630673/en/Securities-Fraud-Investigation-Into-Option-Care-Health-Inc.-OPCH-Continues-Shareholders-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz
The Law Offices of Frank R. Cruz is continuing its investigation into Option Care Health, Inc. (OPCH) for potential federal securities law violations. This comes after the company reported lower-than-expected first-quarter 2026 financial results and reduced its full-year guidance, leading to a significant drop in its stock price. Shareholders who incurred losses are encouraged to contact the law firm for more information regarding a potential claim.

FinancialContent - Option Care Health, Inc. (OPCH) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

https://markets.financialcontent.com/stocks/article/bizwire-2026-5-20-option-care-health-inc-opch-shareholders-who-lost-money-contact-law-offices-of-howard-g-smith-about-securities-fraud-investigation
The Law Offices of Howard G. Smith are investigating Option Care Health, Inc. (OPCH) for potential violations of federal securities laws after the company released disappointing first-quarter 2026 financial results. The financial report, which included missed revenue estimates and a lowered full-year guidance, led to a significant 24.3% drop in Option Care Health's stock price. The firm is encouraging shareholders who suffered losses to contact them regarding potential claims to recover their investment.

Option Care Health (OPCH) Securities Fraud Investigation - Levi & Korsinsky

https://www.prnewswire.com/news-releases/option-care-health-opch-securities-fraud-investigation---levi--korsinsky-302777208.html
Levi & Korsinsky is investigating Option Care Health (OPCH) for potential securities fraud after its shares dropped over 25% on April 30, 2026. The decline followed a Q1 2026 revenue miss and a significant cut in the company's full-year guidance, which had been reaffirmed just 65 days prior. The investigation focuses on whether the company made misleading statements regarding its revenue outlook and the disclosed headwinds related to Stelara biosimilar conversion.
Advertisement

OPCH INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Option Care Health, Inc.

https://www.businesswire.com/news/home/20260519152457/en/OPCH-INVESTOR-ALERT-Kirby-McInerney-LLP-Investigates-Potential-Claims-Involving-Option-Care-Health-Inc.
Kirby McInerney LLP is investigating potential claims on behalf of investors in Option Care Health, Inc. (NASDAQ: OPCH) after the company's shares dropped significantly following its Q1 2026 financial results and lowered full-year guidance. The investigation focuses on whether the company and its management violated federal securities laws, prompted by a 24% stock decline after missed consensus estimates and reduced revenue forecasts. Investors who purchased Option Care Health securities are encouraged to contact the firm to learn more about their rights.

Gamco Investors INC. ET AL Boosts Stock Position in Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-gamco-investors-inc-et-al-boosts-stock-position-in-option-care-health-inc-opch-2026-05-19/
Gamco Investors INC. ET AL increased its stake in Option Care Health (NASDAQ:OPCH) by 36.8% in the fourth quarter, holding 369,002 shares valued at $11.76 million. Other institutional investors have also adjusted their holdings, with 98.05% of the company's stock owned by hedge funds and institutions. Insider transactions show Director Harry M. Jansen Kraemer, Jr. and CEO John Charles Rademacher both acquired significant shares in early May, increasing their respective positions.

What Option Care Health (OPCH)'s Guidance Cut and Insider Buying Signal Means For Shareholders

https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/what-option-care-health-opchs-guidance-cut-and-insider-buyin
Option Care Health (OPCH) recently cut its 2026 guidance due to weaker patient retention and a changed therapy mix, causing a significant stock price drop and prompting legal investigations. Despite this, insider share purchases suggest some confidence in the company's future, with upcoming commentary from senior leadership expected to provide clarity on strategies to stabilize performance. The company's investment narrative projects $6.9 billion revenue and $302.9 million earnings by 2029, with a fair value of $30.73, indicating a potential 57% upside.

Staley Capital Advisers Inc. Sells 75,000 Shares of Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-staley-capital-advisers-inc-sells-75000-shares-of-option-care-health-inc-opch-2026-05-17/
Staley Capital Advisers Inc. reduced its stake in Option Care Health Inc. (NASDAQ:OPCH) by 25% in the fourth quarter, selling 75,000 shares and retaining 225,000 shares valued at approximately $7.17 million. Despite institutional investors collectively owning 98.05% of the stock, several other major institutions increased their holdings in the company. Option Care Health reported strong quarterly EPS of $0.40, exceeding estimates, and analysts currently rate the stock as a "Moderate Buy" with an average price target of $31.25.

Rosen Law Firm Encourages Option Care Health, Inc. Investors to Inquire About Securities Class Action Investigation – OPCH

https://www.businesswire.com/news/home/20260515843356/en/Rosen-Law-Firm-Encourages-Option-Care-Health-Inc.-Investors-to-Inquire-About-Securities-Class-Action-Investigation-OPCH
The Rosen Law Firm has announced an investigation into potential securities claims against Option Care Health, Inc. (NASDAQ: OPCH). This comes after the company reported weak first-quarter 2026 results, including a revenue miss and a lowered full-year financial outlook, which led to a 24.3% drop in stock price on April 30, 2026. The firm is encouraging affected investors to join a prospective class action to recover losses.
Advertisement

Rosen Law Firm Encourages Option Care Health, Inc. Investors to Inquire About Securities Class Action Investigation – OPCH

https://www.joplinglobe.com/region/national_business/rosen-law-firm-encourages-option-care-health-inc-investors-to-inquire-about-securities-class-action/article_bea4028b-7530-5272-b385-d3e2c1ac0363.html
The Rosen Law Firm is investigating potential securities claims against Option Care Health, Inc. (NASDAQ: OPCH) on behalf of investors. This investigation follows a StockStory article on April 30, 2026, which reported a decline in Option Care Health shares after the company announced lower-than-expected first-quarter results and a reduced full-year financial outlook. Investors who purchased Option Care Health securities are encouraged to contact the firm for potential compensation without out-of-pocket fees.

Option Care Health, Inc. (OPCH) Investigation: Bronstein, Gewirtz

https://natlawreview.com/press-releases/option-care-health-inc-opch-investigation-bronstein-gewirtz-grossman-llc
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Option Care Health, Inc. (NASDAQ: OPCH) on behalf of investors. This investigation follows a 26.4% drop in stock price after the company revised its FY 2026 guidance downwards, attributing it to lower patient retention and therapy mix. Shareholders are encouraged to contact the firm to learn more about participating in the investigation.

Leeward Investments LLC MA Purchases 64,868 Shares of Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-leeward-investments-llc-ma-purchases-64868-shares-of-option-care-health-inc-opch-2026-05-15/
Leeward Investments LLC MA increased its stake in Option Care Health, Inc. by 15.3% in the fourth quarter, bringing its total holdings to 488,416 shares valued at approximately $15.6 million. Several other institutional investors also raised their positions, with 98.05% of the stock now institutionally owned. Analysts maintain a "Moderate Buy" rating for OPCH with an average target price of $31.25, while the stock recently traded near $19.95 after exceeding EPS estimates.

Number of shareholders of Option Care Health, Inc. – NASDAQ:OPCH

https://www.tradingview.com/symbols/NASDAQ-OPCH/financials-statistics-and-ratios/number-of-shareholders/
This article provides general financial information for Option Care Health, Inc. (NASDAQ: OPCH), including its number of shareholders. It appears to be a stub or data-oriented page from TradingView, focusing on key financial metrics rather than narrative content. The page also lists various market data providers and copyright information.

Option Care Health, Inc. (OPCH) Presents at Bank of America Global Healthcare Conference 2026 - Slideshow

https://seekingalpha.com/article/4904977-option-care-health-inc-opch-presents-at-bank-of-america-global-healthcare-conference-2026
Option Care Health, Inc. (OPCH) presented a slideshow at the Bank of America Global Healthcare Conference 2026. The article highlights that the slide deck was published by the company in conjunction with this event. SA Transcripts, Seeking Alpha's transcripts team, was responsible for writing this article and publishing the related content.
Advertisement

Bronstein, Gewirtz & Grossman, LLC Is Investigating Option Care Health, Inc. (OPCH) And Encourages Investors to Connect

https://natlawreview.com/press-releases/bronstein-gewirtz-grossman-llc-investigating-option-care-health-inc-opch-0
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Option Care Health, Inc. (OPCH) on behalf of investors. The investigation follows a 26.4% stock price drop after Option Care revised down its FY 2026 guidance, attributing it to lower CID patient retention and therapy mix. The firm is encouraging investors who purchased Option Care securities to assist in the investigation.

OPCH Investor Alert: Levi & Korsinsky Investigates Option Care Health (OPCH) for Potential Securities Fraud

https://www.prnewswire.com/news-releases/opch-investor-alert-levi--korsinsky-investigates-option-care-health-opch-for-potential-securities-fraud-302770573.html
Levi & Korsinsky is investigating Option Care Health (OPCH) for potential securities fraud after the company significantly cut its FY 2026 revenue guidance just 65 days after reaffirming it. Shareholders saw nearly 30% of their investment vanish following Q1 2026 results that missed revenue expectations. The law firm is encouraging investors who suffered losses to contact them to discuss their legal rights regarding the alleged misleading statements.

Option Care Health (NASDAQ:OPCH) Stock Rating Lowered by Zacks Research

https://www.marketbeat.com/instant-alerts/option-care-health-nasdaqopch-stock-rating-lowered-by-zacks-research-2026-05-13/
Zacks Research downgraded Option Care Health (NASDAQ:OPCH) from a "hold" to a "strong sell" rating, despite a broader "Moderate Buy" consensus from other analysts. The stock is currently trading near its 52-week low, significantly below its moving averages, and recently beat earnings expectations. Notably, company insiders, including the CEO and a director, have been recently purchasing shares.

OPTION CARE HEALTH, INC. INVESTOR ALERT: Kirby McInerney LLP Anno

https://natlawreview.com/press-releases/option-care-health-inc-investor-alert-kirby-mcinerney-llp-announces
Kirby McInerney LLP has announced an investigation into potential securities fraud claims against Option Care Health, Inc. (NASDAQ:OPCH). This investigation follows a significant drop in the company's stock price after it lowered its full-year 2026 revenue guidance, missing consensus estimates for Q1 2026 and attributing the revised outlook to "lower CID patient retention and therapy mix." The law firm is seeking investors who may have been affected to discuss their rights.

Option Care Health to Present at Bank of America Health Care Conference, Posts Investor Deck

https://www.tradingview.com/news/tradingview:77f844f526698:0-option-care-health-to-present-at-bank-of-america-health-care-conference-posts-investor-deck/
Option Care Health (OPCH) is scheduled to present at the Bank of America Health Care Conference on May 12, 2026, and has made its investor presentation available. The presentation outlines the company's growth strategy, including reaccelerating revenue growth and reprioritizing capital towards internal investments and share repurchases. The company also highlighted its significant scale, serving over 315,000 patients in 2025 across more than 190 U.S. locations.
Advertisement

Option Care Health (NASDAQ: OPCH) outlines 2026 growth focus

https://www.stocktitan.net/sec-filings/OPCH/8-k-option-care-health-inc-reports-material-event-8a63368825c8.html
Option Care Health (OPCH) has furnished an investor presentation for the Bank of America Health Care Conference, highlighting its position as a leading independent provider of home and alternate site infusion services. The company detailed its extensive network, serving over 315,000 patients in 2025, and outlined its key priorities for 2026. These priorities include reaccelerating revenue growth, reprioritizing capital allocation towards internal investments and share repurchases, and enhancing service levels.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Option Care Health, Inc. (OPCH) And Encourages Stockholders to Reach Out

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1165037
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Option Care Health, Inc. (OPCH) following a significant drop in its stock price. This drop occurred after the Company revised down its FY 2026 guidance, attributing it to lower patient retention and therapy mix. The firm encourages Option Care investors to reach out to assist with the investigation, which is conducted on a contingency fee basis.

Investigation Alert: Option Care Health, Inc. (OPCH) Under Scrutiny - Contact Levi & Korsinsky for Details

https://www.newsfilecorp.com/release/296864/Investigation-Alert-Option-Care-Health-Inc.-OPCH-Under-Scrutiny-Contact-Levi-Korsinsky-for-Details
Levi & Korsinsky has launched an investigation into Option Care Health, Inc. (OPCH) for potential federal securities law violations. This comes after the company reported a Q1 2026 revenue shortfall and subsequently lowered its FY 2026 revenue guidance by up to 3.75%, citing increased headwinds from Stelara biosimilar conversion. The firm encourages investors who suffered losses to contact them to explore potential recovery options.

UBS Group AG Has $29.60 Million Position in Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-has-2960-million-position-in-option-care-health-inc-opch-2026-05-10/
UBS Group AG recently reduced its stake in Option Care Health by 20.3% but still holds a significant position of 928,910 shares valued at approximately $29.6 million. Despite mixed quarterly results where earnings beat estimates but revenue missed and guidance was lowered, insider buying by key executives may signal confidence. Analysts maintain a "Moderate Buy" rating for Option Care Health, even as legal investigations and reputational concerns emerge following the Q1 results.

How Investors May Respond To Option Care Health (OPCH) Revenue Guidance Cut And Chronic Therapy Headwinds

https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/how-investors-may-respond-to-option-care-health-opch-revenue
Option Care Health (OPCH) recently reported Q1 2026 results and cut its full-year revenue guidance due to headwinds in its chronic therapy segment. This revision has triggered securities law investigations and raised concerns about management's ability to foresee patient census trends and therapy mix shifts. The article explores how these challenges and the guidance cut may impact OPCH's long-term investment outlook, emphasizing the need for management to stabilize chronic inflammatory disease volumes and manage payer relationships.
Advertisement

How Investors May Respond To Option Care Health (OPCH) Revenue Guidance Cut And Chronic Therapy Headwinds

https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/how-investors-may-respond-to-option-care-health-opch-revenue/amp
Option Care Health (OPCH) recently reported Q1 2026 results, including a cut in full-year revenue guidance (US$5.68 billion to US$5.78 billion) due to headwinds in its chronic therapy segment. This revision has led to securities law investigations, raising concerns about management's foresight into patient trends and therapy mix. The article suggests investors should focus on the impact of recurring therapy mix resets on revenue quality and the company's efforts to stabilize chronic inflammatory disease volumes.

Van Berkom & Associates Acquires $51.54 Million Stake in Option Care Health

https://www.indexbox.io/blog/van-berkom-associates-acquires-5154-million-stake-in-option-care-health/
Van Berkom & Associates Inc. has disclosed a new $51.54 million stake in Option Care Health, purchasing 1,587,636 shares. This investment, representing 1.41% of the fund's reportable assets, was made before Option Care Health's recent post-earnings decline. The firm views this as a long-term bet on the home infusion services provider, despite recent stock performance and lowered guidance.

Insider Buying: Timothy Sullivan Acquires Shares of Option Care Health Inc (OPCH)

https://www.gurufocus.com/news/8843756/insider-buying-timothy-sullivan-acquires-shares-of-option-care-health-inc-opch?mobile=true
Timothy Sullivan, a Director at Option Care Health Inc (OPCH), recently purchased 24,154 shares, increasing his total holdings to 73,383 shares. This transaction is part of a trend of insider buying at the company, with 10 buys and 2 sells over the last year, indicating confidence. The stock is currently trading at $20.69, which is significantly undervalued compared to its GF Value of $40.26, and has a lower P/E ratio than the industry median.

Option Care Health, Inc. (NASDAQ:OPCH) Given Average Recommendation of "Moderate Buy" by Brokerages

https://www.marketbeat.com/instant-alerts/option-care-health-inc-nasdaqopch-given-average-recommendation-of-moderate-buy-by-brokerages-2026-05-08/
Option Care Health (NASDAQ:OPCH) has received an average "Moderate Buy" recommendation from twelve brokerage firms, with an average 1-year target price of $31.25. Despite recent mixed Q1 earnings and ongoing securities-fraud investigations, company insiders, including two directors and the CEO, have collectively purchased over 73,000 shares, signaling confidence in the company's future. The company reported Q1 EPS of $0.40, beating estimates, but revenue missed projections, leading to trimmed guidance and increased legal risk.

Insider Buying: Option Care Health (NASDAQ:OPCH) Director Acquires 24,154 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-buying-option-care-health-nasdaqopch-director-acquires-24154-shares-of-stock-2026-05-07/
Option Care Health (NASDAQ:OPCH) Director Timothy Sullivan recently purchased 24,154 shares of the company's stock for approximately $499,746, increasing his stake by 49.06%. This insider buying activity comes amidst mixed Q1 financial results, with EPS beating estimates but revenue falling short, and a context of ongoing shareholder investigations and analyst downgrades, which are weighing on investor sentiment. The company has also provided FY2026 EPS guidance, while analysts forecast lower EPS for the current fiscal year.
Advertisement

Director at Option Care Health (OPCH) buys 24,154 company shares

https://www.stocktitan.net/sec-filings/OPCH/form-4-option-care-health-inc-insider-trading-activity-cd4b2dc53345.html
Timothy P. Sullivan, a director at Option Care Health (OPCH), purchased 24,154 shares of the company's common stock at a weighted average price of $20.6869 per share. This open-market transaction, detailed in a Form 4 SEC filing on May 7, 2026, increased his direct holdings to 73,383 shares. The purchase, valued at approximately $500,000, signals a positive sentiment from an insider regarding the company's prospects.

INVESTOR ALERT: Investigation of Option Care Health, Inc. (OPCH) announced by Holzer & Holzer, LLC

https://www.globenewswire.com/news-release/2026/05/07/3290473/0/en/investor-alert-investigation-of-option-care-health-inc-opch-announced-by-holzer-holzer-llc.html
Holzer & Holzer, LLC has announced an investigation into Option Care Health, Inc. (OPCH) regarding potential violations of federal securities laws. This investigation follows the company's Q1 2026 financial results which fell below analyst expectations and led to a lowered full-year revenue outlook, causing a significant drop in its stock price. Shareholders who experienced losses are encouraged to contact the firm to discuss their legal options.

Option Care Health Investors Should Contact Block & Leviton to Possibly Recover Losses

https://www.newsfilecorp.com/release/296311/Option-Care-Health-Investors-Should-Contact-Block-Leviton-to-Possibly-Recover-Losses
Block & Leviton is investigating Option Care Health, Inc. (NASDAQ: OPCH) for potential securities law violations after the company's stock fell over 30% on April 30, 2026. The drop occurred after Option Care Health cut its full-year revenue guidance, attributing it to a larger-than-expected patient census reset. Investors who have experienced losses are encouraged to contact Block & Leviton to explore options for recovering losses and to learn more about the investigation.

Swedbank AB Sells 55,532 Shares of Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-swedbank-ab-sells-55532-shares-of-option-care-health-inc-opch-2026-05-07/
Swedbank AB recently reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 3.1%, selling 55,532 shares, but still maintains a substantial holding of 1,726,000 shares. This divestment occurs amid mixed Q1 results for Option Care Health, where EPS beat estimates but revenue fell short, and several law firms have initiated securities-fraud investigations. Despite these headwinds, insider buying by the CEO and a Director, alongside an "overweight" rating from Morgan Stanley, signals some management confidence.

Option Care Health Price Target Cut to $485.00/Share by Morgan Stanley

https://www.moomoo.com/news/post/69488635/option-care-health-price-target-cut-to-485-00-share
Morgan Stanley has adjusted its price target for Option Care Health (NASDAQ: OPCH) to $485.00 per share, down from the previous target of $490.00. The firm maintained an "Overweight" rating on the stock, indicating a continued positive outlook despite the slight reduction in the price target. This revision comes as part of ongoing analyst evaluations of the company's financial prospects.
Advertisement

OPCH Investors Have Opportunity to Join Option Care Health, Inc. Fraud Investigation with the Schall Law Firm

https://www.globenewswire.com/news-release/2026/05/06/3289502/0/en/opch-investors-have-opportunity-to-join-option-care-health-inc-fraud-investigation-with-the-schall-law-firm.html
The Schall Law Firm is investigating claims on behalf of investors of Option Care Health, Inc. (NASDAQ: OPCH) for potential securities law violations. This investigation follows Option Care's revised downward guidance for FY 2026, citing lower CID patient retention and therapy mix, which led to a 26.4% drop in stock price. Shareholders who suffered losses are encouraged to contact the Schall Law Firm for more information.

FMR LLC (OPCH) reports 6.43M shares; Abigail P. Johnson listed

https://www.stocktitan.net/sec-filings/OPCH/schedule-13g-a-option-care-health-inc-amended-passive-investment-disc-7345f20826da.html
FMR LLC has filed a Schedule 13G/A, disclosing beneficial ownership of 6,426,119.18 shares, representing 4.1% of Option Care Health Inc. (OPCH) common stock. Abigail P. Johnson is listed with sole dispositive power over these shares. The filing indicates a passive investment, as the reported stake is below the 5% threshold typically signaling a more active role.

Option Care Health Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Option Care Health (OPCH)

https://www.morningstar.com/news/pr-newswire/20260506ny52212/option-care-health-investigation-initiated-levi-korsinsky-investigates-the-officers-and-directors-of-option-care-health-opch
Levi & Korsinsky has initiated an investigation into Option Care Health (OPCH) concerning potential misleading statements made by the company's officers and directors. This follows a significant 26.4% stock drop after Option Care Health revised its FY 2026 revenue guidance downward just 65 days after reaffirming it, attributing the change to lower patient retention and therapy mix. The law firm is encouraging investors who suffered losses to contact them to discuss their legal rights.

Executive VP & CFO of Option Care Health Meenal Sethna Buys 20% More Shares

https://simplywall.st/stocks/us/healthcare/nasdaq-opch/option-care-health/news/executive-vp-cfo-of-option-care-health-meenal-sethna-buys-20
Meenal Sethna, Executive VP & CFO of Option Care Health (NASDAQ:OPCH), recently purchased shares worth US$327k at US$20.16 per share, increasing her holding by 20%. This follows a larger insider purchase by Chairman Harry M. Kraemer last year, suggesting confidence in the company. While there has been more insider selling than buying in the last three months, overall insider transactions over the past year show more buying activity.

Insider Buying: Meenal Sethna Acquires Shares of Option Care Hea

https://www.gurufocus.com/news/8840261/insider-buying-meenal-sethna-acquires-shares-of-option-care-health-inc-opch?mobile=true
Meenal Sethna, CFO of Option Care Health Inc (OPCH), recently purchased 16,225 shares, increasing her total holdings to 98,337 shares. This transaction reflects a broader trend of insider confidence, with eight insider buys and two sells over the past year. The stock appears significantly undervalued at $20.16, with a price-to-GF-Value ratio of 0.5, suggesting strong potential based on GuruFocus's intrinsic value estimate.
Advertisement

Option Care Health (NASDAQ:OPCH) Director Purchases $783,820.10 in Stock

https://www.marketbeat.com/instant-alerts/option-care-health-nasdaqopch-director-purchases-78382010-in-stock-2026-05-05/
Option Care Health (NASDAQ:OPCH) Director Harry Jansen Kraemer, Jr. recently purchased 36,610 shares of the company's stock for $783,820.10, increasing his total holdings to 450,000 shares. The company reported strong Q1 EPS of $0.40, beating analyst estimates, and has set its FY 2026 guidance. Institutional investors maintain a significant ownership of 98.05% of the stock, while analysts have a "Moderate Buy" consensus rating with an average target price of $32.08.

Director boosts stake in Option Care Health (OPCH) with 36,610-share buy

https://www.stocktitan.net/sec-filings/OPCH/form-4-option-care-health-inc-insider-trading-activity-90a3e2d80378.html
Option Care Health, Inc. director Harry M. Jansen Kraemer Jr. purchased 36,610 shares of common stock on May 4, 2026, at a weighted average price of $21.4087 per share. This open-market transaction increased his direct ownership to 450,000 shares, reflecting a positive sentiment towards the company. The total value of the purchase was approximately $783,773.

Option Care Health Announces Chief Growth Officer Transition

https://www.tipranks.com/news/company-announcements/option-care-health-announces-chief-growth-officer-transition
Option Care Health announced that Chief Growth Officer Christopher L. Grashoff will depart the company effective May 8, 2026. He will receive severance benefits under the company's executive plan, conditional on signing a claims release and adhering to restrictive covenants. TipRanks' AI Analyst, Spark, rates OPCH as Neutral, noting strong financial health but tempered by margin compression and weaker recent cash conversion, alongside a negative technical trend.

Option care health director Kraemer buys $783,772 in company stock

https://www.investing.com/news/insider-trading-news/option-care-health-director-kraemer-buys-783772-in-company-stock-93CH-4661266
Harry M. Jansen Kraemer Jr., a director at Option Care Health, Inc., recently acquired 36,610 shares of the company's common stock for approximately $783,772. This insider purchase comes as the stock has seen a significant decline, trading down 23% over the past week and 33% year-to-date, with InvestingPro analysis suggesting it is undervalued. The company also announced mixed Q1 2026 earnings, reporting an adjusted EPS that slightly beat estimates but falling short on revenue expectations.

Option Care Health (OPCH) Chief Growth Officer set to exit role May 8, 2026

https://www.stocktitan.net/sec-filings/OPCH/8-k-option-care-health-inc-reports-material-event-f326628868a4.html
Option Care Health, Inc. announced that its Chief Growth Officer, Christopher L. Grashoff, will be departing from his role on May 8, 2026. The company filed an 8-K report clarifying that Mr. Grashoff will receive separation benefits under their Amended and Restated Executive Severance Plan, contingent upon a general release of claims and adherence to restrictive covenants. This leadership change was noted as neutral in sentiment by a corporate governance analyst, with no further details on succession provided in the filing.
Advertisement

Option Care Health, Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton to Possibly Recover Losses

https://www.newsfilecorp.com/release/296050/Option-Care-Health-Inc.-Investigated-for-Securities-Fraud-Investors-Should-Contact-Block-Leviton-to-Possibly-Recover-Losses
Block & Leviton is investigating Option Care Health, Inc. (NASDAQ: OPCH) for potential securities law violations after the company's stock fell over 30% on April 30, 2026. This drop occurred after Option Care Health reported weaker first-quarter results and cut its full-year revenue guidance, attributing it to a larger-than-expected patient census reset in its chronic inflammatory disease portfolio. Investors who suffered losses are encouraged to contact Block & Leviton to explore options for recovery.

Vanguard Group Inc. Sells 1,039,159 Shares of Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-vanguard-group-inc-sells-1039159-shares-of-option-care-health-inc-opch-2026-05-05/
Vanguard Group Inc. reduced its stake in Option Care Health (NASDAQ:OPCH) by 5.9% in the 4th quarter, selling over 1 million shares and now holding a 10.49% stake. Meanwhile, CEO John Charles Rademacher increased his holdings by purchasing 12,500 shares. Option Care Health reported Q1 EPS of $0.40, beating estimates, but revenue missed at $1.35 billion, while analysts maintain a "Moderate Buy" rating with an average price target of $32.08.

Monday’s insider activity: Option Care Health executives buy the dip

https://www.investing.com/news/stock-market-news/mondays-insider-activity-option-care-health-executives-buy-the-dip-93CH-4659111
This article details significant insider buying and selling activity across several U.S. public markets on Monday. Key executives at Option Care Health (OPCH) and S&P Global (SPGI) made substantial purchases, signaling confidence despite recent stock declines. Conversely, insiders at Kinetik Holdings (KNTK), Oklo (OKLO), UWM Holdings (UWMC), Tesla (TSLA), and Antero Resources (AR) engaged in notable stock sales for various reasons, including personal financial planning and trading plans.

Comerica Bank Lowers Holdings in Option Care Health, Inc. $OPCH

https://www.marketbeat.com/instant-alerts/filing-comerica-bank-lowers-holdings-in-option-care-health-inc-opch-2026-05-05/
Comerica Bank significantly reduced its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 84.3% in the fourth quarter, selling 495,886 shares and retaining 92,594 shares valued at $2.95 million. Other institutional investors also adjusted their positions, with some increasing and others decreasing holdings. Analysts have a "Moderate Buy" rating for OPCH shares with a consensus price target of $32.08, while the company's CEO recently acquired a substantial number of shares.

Insider Buying: Option Care Health (NASDAQ:OPCH) CEO Acquires 12,500 Shares of Stock

https://www.marketbeat.com/instant-alerts/insider-buying-option-care-health-nasdaqopch-ceo-acquires-12500-shares-of-stock-2026-05-04/
Option Care Health CEO John Charles Rademacher recently purchased 12,500 shares of the company's stock, increasing his total holdings to 695,152 shares. This transaction, valued at $264,750, follows the company's Q1 earnings report where it surpassed EPS estimates but slightly missed revenue expectations. Despite the stock trading below its 50- and 200-day averages, Wall Street analysts maintain a "Moderate Buy" consensus with a target price of $32.08.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement